GlycoPharma Holding ApS: Financial statements 2020
CVR: 39691558
Source: annual report 2020, Danish Business Authority
01/07/2019 – 30/06/2020
GlycoPharma Holding ApS (CVR 39691558) has filed annual accounts for 2020. In 2020, the company reported a gross profit of DKK -7,467 and a net result of DKK -618 compared with DKK -5,871 the year before. Equity in the 2020 report amounted to DKK 314,056. The solvency ratio was 77.5%.
- Gross Profit
- DKK -7,467
- Profit/Loss
- DKK -618
- Equity
- DKK 314,056
- Total Assets
- DKK 404,974
Official annual report
How creditworthy is GlycoPharma Holding ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreAbout GlycoPharma Holding ApS
GlycoPharma Holding ApS is a Danish company of the type Anpartsselskab based in Odense SØ, founded in 2018. The company is registered under the industry Ikke-finansielle holdingselskaber. The management consists of Anders Boysen. The company's owners include SCIENCE VENTURES DENMARK A/S, Boysen Bio ApS and Zahle Holding ApS. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -12,525 and a net result of DKK -12,441 compared with DKK -15,360 the year before. Equity in the 2025 report amounted to DKK 684,140.